Eyevensys, a Biotechnology company raises $10M funding from Pontifax Venture Capital & existing investors

Eyevensys develops therapies for the treatment of ocular diseases by non viral gene therapy

Paris - Sept 15, 2016. RedNewswire/-

Eyevensys is a private biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease.

It uses two technologies, Electro-Transfection (Electro-Transfection of plasmids to the ciliary muscle) and Drug Device solution ( Electro-Transfection Injection System (ETIS)) for the treatment of eye diseases.

It has raised $10M in Series A funding round led by BpifrancePontifax Venture Capital and existing investors Boehringer Ingelheim Venture FundInserm Transfert Initiative  & CapDecisif.

The funds raised will be used to secure the clinical development of its products, pipeline includes EYS-606, a soluble TNFa receptor plasmid and EYS609, a device-plasmid combination method to express a anti-VEGF compound in-situ in the eye over extended periods of time. 

The company has partnered with Eurogentec, Fesys, CytoxLab, Axonal and others to develop its technology.

Featured image source